A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naive Patients
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Alisporivir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Debiopharm; Novartis; Novartis Pharma
- 28 Jun 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 24 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 16 Sep 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.